ALEXANDRIA, Va. – An analysis of nearly 2,800 people with non-small cell lung cancer (NSCLC) who received the immune checkpoint inhibitors nivolumab (Opdivo), pembrolizumab (Keytruda), or atezolizumab (Tecentriq) found that unexpected medical problems, known as adverse events, may be more common than reported in the initial trials that led to the approval of these therapies. These findings will be presented at the upcoming 2018 Palliative and Supportive Care in Oncology Symposium in San Diego, California.
ALEXANDRIA, Va. – A study of 112 people with metastatic solid tumors found that the use of an artificial intelligence (AI)-based smartphone app reduced both the severity of patients’ reported pain and hospital admissions. After an eight-week period, patients who used the AI-powered app to monitor and address pain experienced a 20% reduction in the severity of pain and had nearly 70% lower risk of pain-related hospital admissions than patients not using the app. These findings will be presented at the upcoming 2018 Palliative and Supportive Care in Oncology Symposium in San Diego, California.
ALEXANDRIA, Va. –– Organizers of the 2018 Palliative and Supportive Care in Oncology Symposium announced today two abstracts will be highlighted in the meeting’s official Press Program.
ALEXANDRIA, Va. – New studies released today reveal the financial difficulties that people living with cancer currently face. The research looks at financial distress, also known as “financial toxicity,” among patients with metastatic breast cancer and older patients, as well as conversations about cost of care that women with breast cancer are having with their physicians. Authors will present their findings at the American Society of Clinical Oncology’s (ASCO) upcoming Quality Care Symposium, taking place September 28–29, in at the JW Marriott Phoenix Desert Ridge in Phoenix.
ALEXANDRIA, Va. – In the midst of the national opioid epidemic, two new studies explore opioid use in cancer care. The studies compared opioid deaths among cancer patients to the general population and looked at an initiative to reduced opioid use after oncology surgeries. Authors will present their findings at the American Society of Clinical Oncology’s (ASCO) upcoming Quality Care Symposium, taking place September 28–29, in at the JW Marriott Phoenix Desert Ridge in Phoenix.
CHICAGO – A randomized, phase III trial found that people who received chemotherapy with radiation (chemoradiotherapy) before pancreatic cancer surgery had better disease-free survival than those who started their treatment with surgery, which is the current standard of care. In addition, the two-year survival rate was higher for those who received chemoradiotherapy before surgery (42% vs. 30%). The preliminary findings of this trial show that chemoradiotherapy before surgery may be beneficial for patients with pancreatic cancer.
CHICAGO – In a randomized phase III trial people with surgically removed pancreatic cancer who received mFOLFIRINOX, a chemotherapy regimen containing four different medicines, lived a median of 20 months longer and were cancer-free nine months longer than those who received the current standard of care, gemcitabine (Gemzar®).
CHICAGO – A randomized phase III clinical trial shows that people with advanced colorectal cancer may not need a frequently considered component of treatment – heated chemotherapy delivered to the abdomen during surgery. There was no difference in survival between patients with metastases in the abdomen who received heated chemotherapy during surgery and those who received surgery alone. Long-term side effects were more common with chemotherapy.
CHICAGO – Findings from an updated analysis from a randomized phase III trial show that taking a high dose of the acid-reducing medicine esomeprazole (Nexium®) with low dose aspirin for at least seven years can moderately reduce the risk of developing high grade dysplasia (a pre-cancerous lesion) or esophageal cancer, or delay death from any cause in people with Barrett’s esophagus.
CHICAGO – A federally funded phase III clinical trial shows that most women with hormone receptor-positive, HER2-negative, axillary node-negative early-stage breast cancer and a mid-range score on a 21-tumor gene expression assay (Oncotype DX® Breast Recurrence Score) do not need chemotherapy after surgery. The study found no improvement in disease-free survival when chemotherapy was added to hormone therapy in this group, which accounts for about two-thirds of women who participated in the trial. The findings will have an immediate impact on clinical practice, sparing thousands of women the side effects of chemotherapy.
CHICAGO – A randomized phase III clinical trial showed that many people with advanced kidney cancer can avoid surgery to remove the kidney (nephrectomy), without compromising survival. The median overall survival for people who received only the targeted therapy sunitinib (Sutent®) was 18.4 months, compared to 13.9 months for those who received surgery followed by sunitinib, the current standard of care.
CHICAGO – A new chemotherapy strategy improves cure rates for children with rhabdomyosarcoma (a rare cancer of the muscle tissue) who are at high risk for cancer recurrence. In a randomized phase III clinical trial, adding six months of low-dose maintenance chemotherapy after initial treatment increased the 5-year overall survival rate from 73.7% to 86.5%. Children with rhabdomyosarcoma who are alive at five years are considered cured, as tumor recurrence is very rare.
CHICAGO – A large, randomized phase III trial shows that the immunotherapy pembrolizumab (Keytruda®) is a more effective initial treatment than chemotherapy (the current standard of care) for the majority of patients with the most common type of lung cancer. People with advanced non-small-cell lung cancer (NSCLC) with a PD-L1 expression of 1% or more who were first treated with immunotherapy pembrolizumab lived a median of 4-8 months longer than those who received chemotherapy. In addition, severe side effects occurred in fewer patients receiving pembrolizumab than chemotherapy (18% vs. 41%).
CHICAGO – In a phase III clinical trial, a new targeted medicine, taselisib, combined with standard hormone therapy fulvestrant (Faslodex®), halted the growth of advanced breast cancer growth by 2 months longer than hormone therapy alone, and decreased the chance of cancer worsening by 30%. Taselisib targets a common genetic abnormality in breast cancer – PIK3CA gene mutation – and is the first and most potent treatment in a relatively new class of PI3K inhibitors, according to the authors.
CHICAGO – A genomic study of more than 15,000 tumor samples shows that people with tumors that have high microsatellite instability (MSI-H) – a genomic marker associated with a large number of genetic mutations in the tumor – are more likely to have Lynch syndrome, a hereditary condition that increases a person’s risk of developing many different types of cancer. Among people with MSI-H tumors, 16% were subsequently found to have Lynch syndrome. Researchers also found that Lynch syndrome is linked to more types of cancer than previously thought.